Michael Davidson Net Worth

The estimated Net Worth of Michael H. Davidson is at least $1.24 Thousand dollars as of 8 August 2024. Michael Davidson owns over 2,500 units of Caladrius Biosciences Inc stock worth over $1,239 and over the last 4 years he sold CLBS stock worth over $0. In addition, he makes $0 as Director at Caladrius Biosciences Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Michael Davidson CLBS stock SEC Form 4 insiders trading

Michael has made over 2 trades of the Caladrius Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 2,500 units of CLBS stock worth $1,075 on 8 August 2024.

The largest trade he's ever made was buying 55,525 units of Caladrius Biosciences Inc stock on 9 September 2020 worth over $99,945. On average, Michael trades about 8,289 units every 204 days since 2020. As of 8 August 2024 he still owns at least 2,881 units of Caladrius Biosciences Inc stock.

You can see the complete history of Michael Davidson stock trades at the bottom of the page.

Michael Davidson biography

Dr. Michael H. Davidson serves as Director of the Company. Dr. Davidson is a nationally recognized expert in lipidology and has been named one of "The Best Doctors in America" by Best Doctors Inc. for the past 10 years. Dr. Davidson was the co-founding Chief Medical Officer of Omthera Pharmaceuticals in 2008, which was later acquired by Astra Zeneca Pharmaceutical in 2013. He also founded the Chicago Center for Clinical Research, which became the largest investigator site in the United States and was acquired by Pharmaceutical Product Development in 1996. His research and clinical development background encompass both pharmaceutical and nutritional clinical trials, including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Michael is board-certified in internal medicine, cardiology and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. He received his BA and M.S from Northwestern University and an MD from The Ohio State University School of Medicine.

How old is Michael Davidson?

Michael Davidson is 59, he's been the Director of Caladrius Biosciences Inc since 2020. There are 9 older and 5 younger executives at Caladrius Biosciences Inc. The oldest executive at Caladrius Biosciences Inc is Steven Myers, 73, who is the Independent Director.

What's Michael Davidson's mailing address?

Michael's mailing address filed with the SEC is 101 GLEN LENNOX DRIVE, SUITE 300, , CHAPEL HILL, NC, 27517.

Insiders trading at Caladrius Biosciences Inc

Over the last 9 years, insiders at Caladrius Biosciences Inc have traded over $244,786 worth of Caladrius Biosciences Inc stock and bought 202,695 units worth $275,173 . The most active insiders traders include Richard J Berman, Steven M Klosk, and Peter G Traber. On average, Caladrius Biosciences Inc executives and independent directors trade stock every 178 days with the average trade being worth of $17,064. The most recent stock trade was executed by Steven S Myers on 8 December 2021, trading 33,785 units of CLBS stock currently worth $30,069.

What does Caladrius Biosciences Inc do?

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).

Complete history of Michael Davidson stock trades at Caladrius Biosciences Inc and Tenax Therapeutics Inc

Caladrius Biosciences Inc executives and stock owners

Caladrius Biosciences Inc executives and other stock owners filed with the SEC include:

• David Mazzo,
  President, Chief Executive Officer, Director
• Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.,
  Pres, CEO & Director
• Dr. William K. Sietsema Ph.D.,
  VP of Global Regulatory Affairs
• Robert Honigberg,
  Interim Chief Medical Officer
• Anne Whitaker,
  Director
• Michael Davidson,
  Director
• Todd Girolamo,
  Senior Vice President, General Counsel, Corporate Secretary
• Peter Traber,
  Independent Director
• Steven Myers,
  Independent Director
• Steven Klosk,
  Independent Director
• Cynthia Schwalm,
  Independent Director
• Gregory Brown,
  Independent Chairman of the Board
• Dr. Kristen K. Buck M.D.,
  Exec. VP of R&D and Chief Medical Officer
• James Nisco,
  VP of Fin. & Treasury
• Dr. Ian Zhang Ph.D., MBA,
  Pres of NeoStem (China), Inc and Managing Director of NeoStem (China), Inc
• Dr. Robert M. Honigberg,
  Interim Chief Medical Officer
• Gail Holler,
  VP of HR
• Eric Powers,
  Director of Communications and Marketing
• Todd C. Girolamo M.B.A., J.D., Esq.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• John D. Menditto,
  VP of Investor Relations & Corp. Communications
• Gregory S. Berkin,
  VP of Information Technology & Cyber security and Chief Information Officer
• Eric Wei,
  Director
• Richard J Berman,
  Director
• Douglas W Losordo,
  See Remarks
• Robert A Preti,
  See Remarks
• Cynthia Louise Flowers,
  Director
• Joseph Talamo,
  SVP and CFO
• Robert S Vaters,
  President & CFO
• Kristen K Buck,
  EVP, R&D and CMO